Lista de obras -

A case of late-onset Tourette's disorder successfully treated with aripiprazole: view from blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF).

artículo científico publicado en 2009

A case of schizophrenia with Meige syndrome induced by long-term aripiprazole successfully treated with perospirone ⬇️

artículo científico publicado el 16 de septiembre de 2010

A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder

artículo científico publicado en 2009

A close correlation between plasma and serum levels of brain-derived neurotrophic factor (BDNF) in healthy volunteers

artículo científico publicado en 2010

Abnormal white matter integrity in the corpus callosum among smokers: tract-based spatial statistics

artículo científico publicado en 2014

Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study

artículo científico publicado en 2008

Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression

artículo científico publicado en 2009

Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

artículo científico publicado en 2008

Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients

artículo científico publicado en 2011

Aripiprazole improves various cognitive and behavioral impairments after traumatic brain injury: a case report ⬇️

artículo científico publicado el 14 de junio de 2012

Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study

artículo científico publicado en 2010

Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia

artículo científico publicado en 2009

Blood levels of brain-derived neurotrophic factor (BDNF) in major depressive disorder

artículo científico publicado en 2010

Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea

artículo científico publicado en 2009

Brain-derived neurotrophic factor (BDNF) and mood disorder

artículo científico publicado en 2010

COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study

artículo científico publicado en 2014

Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder

artículo científico publicado en 2015

Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder

artículo científico publicado en 2014

Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder

artículo científico publicado en 2012

Current smoking rate in patients with psychiatric disorders in Japan: Questionnaire survey ⬇️

artículo científico publicado el 17 de abril de 2013

Decreased Activity at the Time of Return to Work Predicts Repeated Sick Leave in Depressed Japanese Patients

artículo científico publicado en 2016

Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients

artículo científico publicado en 2010

Does subjective sleep quality improve by a walking intervention? A real-world study in a Japanese workplace

artículo científico publicado en 2016

Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder

artículo científico publicado en 2014

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone

artículo científico

Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders

artículo científico publicado en 2006

Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients

scientific article published on 01 October 2007

Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine

artículo científico publicado en 2009

Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients

artículo científico publicado en 2007

Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients

artículo científico publicado en 2007

Effects of the number of hospitalizations on cognitive function in Japanese patients with stable schizophrenia

scientific article published on 04 September 2020

Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study

artículo científico publicado en 2008

Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms

scientific article published on 01 January 2009

Follow-up Study on Electroconvulsive Therapy in Treatment-resistant Depressed Patients after Remission: A Chart Review ⬇️

artículo científico publicado el 24 de abril de 2013

Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers

artículo científico publicado en 2009

Gray and white matter volumetric and diffusion tensor imaging (DTI) analyses in the early stage of first-episode schizophrenia

artículo científico publicado en 2009

Herbal medicine (Shakuyaku-kanzo-to) improves olanzapine-associated hyperprolactinemia: a case report

scientific article published on 01 February 2013

Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression

artículo científico publicado en 2009

No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients ⬇️

artículo científico publicado el 30 de abril de 2012

No alterations of brain GABA after 6months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia ⬇️

artículo científico publicado el 19 de agosto de 2010

No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients ⬇️

artículo científico publicado el 16 de junio de 2011

No difference in adherence to paroxetine between depressed patients with early remission and those with late remission based on monitoring of plasma paroxetine concentrations ⬇️

artículo científico publicado el 1 de agosto de 2010

No significant association between brain-derived neurotrophic factor gene rs6265 and cognitive function in Japanese patients with schizophrenia

artículo científico publicado en 2014

Nonadherence to paroxetine: a study based on monitoring plasma paroxetine levels

artículo científico publicado en 2010

Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study

artículo científico publicado en 2009

Plasma Levels of Metabolites of Catecholamine in Nicotine-Dependent Patients Treated With Varenicline ⬇️

artículo científico publicado el 17 de octubre de 2011

Plasma catecholamine metabolite levels and the activities of psychiatric symptoms in systemic lupus erythematosus ⬇️

artículo científico publicado el 1 de marzo de 2013

Plasma levels of 3-methoxy-4-hydroxyphenylglycol are associated with microstructural changes within the cerebellum in the early stage of first-episode schizophrenia: a longitudinal VBM study

artículo científico publicado en 2014

Plasma levels of brain‐derived neurotrophic factor and interleukin‐6 in patients with dysthymic disorder: comparison with age‐ and sex‐matched major depressed patients and healthy controls ⬇️

artículo científico publicado el 1 de noviembre de 2010

Plasma levels of interleukin‐6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder ⬇️

artículo científico publicado el 30 de junio de 2013

Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism

artículo científico publicado en 2009

Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.

artículo científico publicado en 2009

Relationship between G1287A of the NET Gene Polymorphisms and Brain Volume in Major Depressive Disorder: A Voxel-Based MRI Study

artículo científico publicado en 2016

Relationships between brain-derived neurotrophic factor, clinical symptoms, and decision-making in chronic schizophrenia: data from the Iowa Gambling Task

artículo científico publicado en 2014

Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy

artículo científico publicado en 2016

Relationships between stress, social adaptation, personality traits, brain-derived neurotrophic factor and 3-methoxy-4-hydroxyphenylglycol plasma concentrations in employees at a publishing company in Japan ⬇️

artículo científico publicado el 15 de septiembre de 2010

Reliability, validity and clinical utility of a Japanese version of the Social Adaptation Self‐evaluation Scale as calibrated using the Beck Depression Inventory ⬇️

artículo científico publicado el 1 de diciembre de 2011

Risk factors for further sick leave among Japanese workers returning to work after an episode of major depressive disorder: a prospective follow-up study over 1 year

scientific article published on 11 September 2019

Serum Brain–Derived Neurotrophic Factor Levels at 6 Months After Remission Are Not Associated With Subsequent Depressive Episodes ⬇️

artículo científico publicado el 1 de febrero de 2013

Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs.

artículo científico publicado en 2014

Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus

artículo científico publicado en 2010

Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD) ⬇️

artículo científico publicado el 10 de agosto de 2012

Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia

artículo científico publicado en 2016

Serum levels of brain-derived neurotrophic factor in comorbidity of depression and alcohol dependence.

artículo científico publicado en 2009

Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients.

artículo científico publicado en 2014

Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients ⬇️

artículo científico publicado el 5 de diciembre de 2011

Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia ⬇️

artículo científico publicado el 3 de abril de 2012

Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?

artículo científico publicado en 2007

Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients

artículo científico publicado en 2013

The Effects of a Walking Intervention on Depressive Feelings and Social Adaptation in Healthy Workers ⬇️

artículo científico publicado el 1 de marzo de 2013

The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients

artículo científico publicado en 2011

The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients ⬇️

artículo científico publicado el 29 de marzo de 2012

Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa

scientific article published on 01 August 2007

Three polymorphisms of the eNOS gene and plasma levels of metabolites of nitric oxide in depressed Japanese patients: a preliminary report

artículo científico publicado en 2011

Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients

artículo científico publicado en 2007

Two cases of burning mouth syndrome treated with olanzapine

artículo científico publicado en 2008

Varenicline does not increase serum BDNF levels in patients with nicotine dependence

artículo científico publicado en 2010

[Role of Psychiatry in Occupational Health: Focus on Stress Check System in Japan]

artículo científico publicado en 2017

Lista de obras de

A case of late-onset Tourette's disorder successfully treated with aripiprazole: view from blood levels of catecholamine metabolites and brain-derived neurotrophic factor (BDNF).

A case of schizophrenia with Meige syndrome induced by long-term aripiprazole successfully treated with perospirone ⬇️

A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder

A close correlation between plasma and serum levels of brain-derived neurotrophic factor (BDNF) in healthy volunteers

Abnormal white matter integrity in the corpus callosum among smokers: tract-based spatial statistics

Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study

Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression

Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline

Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients

Aripiprazole improves various cognitive and behavioral impairments after traumatic brain injury: a case report ⬇️

Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study

Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia

Blood levels of brain-derived neurotrophic factor (BDNF) in major depressive disorder

Blood levels of catecholamine metabolites and brain-derived neurotrophic factor in a case of Sydenham's chorea

Brain-derived neurotrophic factor (BDNF) and mood disorder

COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study

Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder

Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder

Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder

Current smoking rate in patients with psychiatric disorders in Japan: Questionnaire survey ⬇️

Decreased Activity at the Time of Return to Work Predicts Repeated Sick Leave in Depressed Japanese Patients

Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients

Does subjective sleep quality improve by a walking intervention? A real-world study in a Japanese workplace

Duloxetine, a Selective Noradrenaline Reuptake Inhibitor, Increased Plasma Levels of 3-Methoxy-4-hydroxyphenylglycol but Not Homovanillic Acid in Patients with Major Depressive Disorder

Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone

Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders

Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients

Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine

Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients

Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients

Effects of the number of hospitalizations on cognitive function in Japanese patients with stable schizophrenia

Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study

Fluctuating plasma levels of the active moiety of risperidone is related to occurrence of extrapyramidal symptoms

Follow-up Study on Electroconvulsive Therapy in Treatment-resistant Depressed Patients after Remission: A Chart Review ⬇️

Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers

Gray and white matter volumetric and diffusion tensor imaging (DTI) analyses in the early stage of first-episode schizophrenia

Herbal medicine (Shakuyaku-kanzo-to) improves olanzapine-associated hyperprolactinemia: a case report

Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression

No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients ⬇️

No alterations of brain GABA after 6months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia ⬇️

No association between BDNF Val66Met polymorphism and emergence of psychiatric symptoms in systemic lupus erythematosus patients ⬇️

No difference in adherence to paroxetine between depressed patients with early remission and those with late remission based on monitoring of plasma paroxetine concentrations ⬇️

No significant association between brain-derived neurotrophic factor gene rs6265 and cognitive function in Japanese patients with schizophrenia

Nonadherence to paroxetine: a study based on monitoring plasma paroxetine levels

Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study

Plasma Levels of Metabolites of Catecholamine in Nicotine-Dependent Patients Treated With Varenicline ⬇️

Plasma catecholamine metabolite levels and the activities of psychiatric symptoms in systemic lupus erythematosus ⬇️

Plasma levels of 3-methoxy-4-hydroxyphenylglycol are associated with microstructural changes within the cerebellum in the early stage of first-episode schizophrenia: a longitudinal VBM study

Plasma levels of brain‐derived neurotrophic factor and interleukin‐6 in patients with dysthymic disorder: comparison with age‐ and sex‐matched major depressed patients and healthy controls ⬇️

Plasma levels of interleukin‐6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder ⬇️

Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism

Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients.

Relationship between G1287A of the NET Gene Polymorphisms and Brain Volume in Major Depressive Disorder: A Voxel-Based MRI Study

Relationships between brain-derived neurotrophic factor, clinical symptoms, and decision-making in chronic schizophrenia: data from the Iowa Gambling Task

Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy

Relationships between stress, social adaptation, personality traits, brain-derived neurotrophic factor and 3-methoxy-4-hydroxyphenylglycol plasma concentrations in employees at a publishing company in Japan ⬇️

Reliability, validity and clinical utility of a Japanese version of the Social Adaptation Self‐evaluation Scale as calibrated using the Beck Depression Inventory ⬇️

Risk factors for further sick leave among Japanese workers returning to work after an episode of major depressive disorder: a prospective follow-up study over 1 year

Serum Brain–Derived Neurotrophic Factor Levels at 6 Months After Remission Are Not Associated With Subsequent Depressive Episodes ⬇️

Serum Levels of Brain-Derived Neurotrophic Factor at 4 Weeks and Response to Treatment with SSRIs.

Serum brain-derived neurotrophic factor levels as a novel biological marker for the activities of psychiatric symptoms in systemic lupus erythematosus

Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD) ⬇️

Serum levels of brain-derived neurotrophic factor (BDNF), proBDNF and plasma 3-methoxy-4-hydroxyphenylglycol levels in chronic schizophrenia

Serum levels of brain-derived neurotrophic factor in comorbidity of depression and alcohol dependence.

Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients.

Several prescription patterns of antipsychotic drugs influence cognitive functions in Japanese chronic schizophrenia patients ⬇️

Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia ⬇️

Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?

Switching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patients

The Effects of a Walking Intervention on Depressive Feelings and Social Adaptation in Healthy Workers ⬇️

The brain-derived neurotrophic factor (BDNF) polymorphism Val66Met is associated with neither serum BDNF level nor response to selective serotonin reuptake inhibitors in depressed Japanese patients

The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients ⬇️

Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa

Three polymorphisms of the eNOS gene and plasma levels of metabolites of nitric oxide in depressed Japanese patients: a preliminary report

Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients

Two cases of burning mouth syndrome treated with olanzapine

Varenicline does not increase serum BDNF levels in patients with nicotine dependence

[Role of Psychiatry in Occupational Health: Focus on Stress Check System in Japan]